2nd Symposium on Advances in Cancer Immunology and Immunotherapy

Organized by Hellenic Society of Immuno-Oncology

December 15-17 2016
Royal Olympic Hotel
Athens, Greece

http://hellenic-immunooncology.gr/2soio/

Under the auspices of

SCEP Scientific Cultural Events and Publications
T +30 210 7240039 F +30 210 7240139 E info@scep.gr www.scep.gr
Dear Colleagues,

The Hellenic Society of Immuno-Oncology organizes the 2nd Symposium on "Advances in Cancer Immunology and Immunotherapy" which will be held on December 15th –17th 2016, at the Royal Olympic Hotel, Athens, Greece.

The field of tumor immunology and immunotherapy has entered a new era and our expanding knowledge of immune regulation has already led to innovative therapies for the treatment of cancer. The Symposium aims to bring together clinical and translational oncologists and immunologists to present most recent cutting-edge advances in the stimulating field of cancer immunotherapy. Distinguished invited speakers from leading Institutions in Europe and overseas will report on novel immunotherapeutic strategies leading to effective clinical responses, highlight the significance of prognostic and predictive cancer biomarkers in determining clinical outcome, analyse the principles of cancer immune surveillance and immune suppression, and exploit the potency of combinatorial treatments that can eventually contribute to promising anti-cancer therapeutic interventions. We aim to bring together researchers and clinicians working in these areas, promote interactions between speakers and participants, encourage stimulating discussions, exchange of ideas and experiences, and facilitate the establishment of contacts for new collaborations. In particular, young researchers will be offered the opportunity to present their work to an audience of eminent scientists and receive feedback that will impact on their scientific development in the fields of cancer immunology and immunotherapy.

Athens (Αθήνα) is the capital and the largest city of Greece. It is one of the world’s oldest cities, with its recorded history spanning around 3,400 years, and the earliest human presence around the 11th–7th millennium BC. Athens hosts

On behalf of the Organizing and Scientific Committees, we are pleased to invite you to participate in this Symposium. We very much look forward seeing you this December in Athens.

Kind regards,

The Organizing Committee

Athanasios Kotsakis, MD, PhD
Asst. Professor of Medical Oncology, University Hospital of Heraklion & Laboratory of Translational Oncology, School of Medicine, University of Crete, Greece

Ouraias Tsisilonis, MD, PhD
Assoc. Professor of Immunology, Dept. of Animal and Human Physiology, Faculty of Biology, National & Kapodistrian University of Athens, Greece

Nikolaos Kentepozidis, MD, PhD
Medical Oncologist, Head of Oncology Clinic, 251 General Airforce Hospital, Athens, Greece

The Scientific Committee Chairs

Constantin N. Baxevanis, PhD
Scientific Director, Cancer Immunology and Immunotherapy Center "Agios Savvas" Hospital, Athens, Greece

Vassileios Georgoulis, MD, PhD
Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Marinos Tsitas, MD, PhD
Medical Oncologist, Athens Medical Center, Greece

Confirmed Speakers

Prof. Geras J. Adema, Chair in Molecular Immunology, Department of Tumor Immunology, RIVM/IL 278 TIL, Radboud University Medical Centre, Nijmegen, The Netherlands

Prof. Athanasios Argiris, MD, PhD, FACCP, Consultant Medical Oncologist, Hygeia Hospital/ Professor, Medical Oncology, Thomas Jefferson University, USA, Adjunct Professor, University of Texas, USA

Dr. Dimitrios Bafaloukos, MD, PhD, Medical Oncologist, Head, First Department of Medical Oncology, Metropolitan Hospital, Athens, Greece

Prof. Constantin N. Baxevanis, Scientific Director, Cancer Immunology and Immunotherapy Center “Agios Savvas” Hospital, Athens, Greece

Dr. Davide Bedognetti, MD, PhD, Director, Tumor Biology, Immunology, and Therapy, Division of Translational Medicine, Research Branch, Sida Medical and Research Center, Out-Patient Clinic, Education City North Campus, Doha, Qatar Foundation

Prof. Rossana Bernardi, MD, Head of Dept of Medical Oncology, Director of the Postgraduate School of Medical Oncology, Director of “Genetic Cancer” Center, Deputy Director of Dept of Clinical and Molecular Science, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I – EM Lancia – G Salesi, Ancona, Italy

Prof. Vincenzo Bontchi, Head of Immunology Section, Department of Pathology and Diagnostics, Verona University, Italy

Dr. Dr. Julie Y. Djou, Senior Member, Immunology Program, H. Lee Moffitt Cancer Center & Research Institute, Associate Center Director for Education and Training, Tampa, FL, United States

Dr. Christos Emmanouilides, MD, PhD, Medical Oncologist, Interthalassic medical Center, Thessaloniki, Greece/ Assoc Professor Of Medicine At UCLA (J)

Prof. Zelig Eshhar, The Marshall and Renette Erazlow Professor of Chemical and Cellular Immunology, Weizmann Institute of Science, Rehovot, Israel

Prof. Zvi G. Fridlander, MD, MSc., Head, Center for COPD & smoking damage, Head, Laboratory of lung cancer research, Secretary, Israel Society of Pulmonology Inst of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Prof. Wolf H. Fridman, Professor of Immunology, Laboratory Cancer, Immune Control and Escape, Cordeliers Research Centre, Paris, France- University Pierre and Marie Curie

Prof. Ravit Geva, Senior Physician, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

PD Dr. Cécile Gouttefangeas, Group leader at the Institute for Cell Biology, Department of Immunology, Tübingen, Germany

Prof. Dominique Heymann, Professor of Bone Oncology, Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK

Dr. Niki Karachaliou, MD, Medical Oncologist, Translational Research Group, Panagena Biotech, USP Instituto Universitario Dixiew, Barcelona, Spain

Prof. Nathan Karin, PhD, Professor of Immunology, Department of Immunology, Chairmann, Rappaport Inst., Rappaport Faculty of Medicine, Technion, Haifa, Israel

Dr. Nikolaos Kentepozidis, MD, PhD, Medical Oncologist, Head of Oncology Clinic, 251 General Airforce Hospital, Athens, Greece

Dr. Konstantas Kostopoulou, Scientific Director Vaxon Biotech, Paris, France

Prof. Athanasios Kotsakis, MD, PhD, Asst. Professor of Medical Oncology, School of Medicine, University of Crete, Greece

Dr. Vassilis Kouloulias, As. Professor Radiation Oncology, MS,MD,PhD, 2nd Dept Radiology, Medical School, University of Athens, Greece

Prof. Ed Lavelle, Adjunt Research, School of Biochemistry and Immunology, Trinity College, Dublin

Dr. med. Yannis Metaxas, Senior Physician Oncology / Hematology, Kantorssopal Gruabünde, Chur, Switzerland

Prof. Dr. Graham Pawelec, Professor of Experimental Immunology, Center of Medical Research, Second Department of Internal Medicine, University of Tubingen, Germany

Prof. Paul W. O’Toole, PhD, Microbial Genomics, School of Microbiology & APC Microbiome Institute, University College Cork, Ireland

Dr. Licia Rivoltini, MD, Head of the Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Dr. Andreas Scorilas, PhD Professor of Clinical Biochemistry, Head, Department of Biochemistry and Molecular Biology/University of Athens, Greece

Dr. Barbara Seliger, Martin Luther University, Medical Faculty, Institute for Medical Immunology, Halle, Germany

Dr. A Marcelis Szasz, Research Fellow, 2nd Department of Pathology, Semmelweis University, Hungary

Dr. Marinos Tsitas, MD, PhD, Medical Oncologist, Athens Medical Center, Greece

Prof. Viktor Umansky, PhD, Clinical Cooperation Unit Dermato-Oncology (G300), German Cancer Research Center (DKFZ), Foundation under Public Law, Heidelberg, Germany

Dr. Panayotis Verginis, PhD, Investigator - Lecturer Level, Biomolecular Research Foundation of the Academy of Athens

Prof. Dr. Theresa L. Whitesides, Professor of Pathology, Immunology and Otolaryngology, University of Pittsburgh Cancer Institute, USA
The scientific program will include sessions on the following topics:

- New developments in cancer biomarkers
- Immune suppression in cancer
- Immune-oriented cancer therapies
- Immune stimulation in cancer
- Immunotherapy for Non-Small Cell Lung Cancer
- Immunotherapy for prostate cancer
- Update on immunotherapy of bladder cancer
- Immunotherapy for renal carcinoma
- Immunotherapy for breast cancer
- Immunotherapy for GI malignancies
- Immunotherapy for melanoma
- Novel cancer immunotherapeutic approaches
- Immunotherapy for melanoma
- Immunotherapy for renal carcinoma
- Immunotherapy for breast cancer
- Immunotherapy for GI malignancies
- Immunotherapy for melanoma
- Novel cancer immunotherapeutic approaches

**Main Topics**

**Invited Program**
- Lectures
- Plenary lectures
- Keynote lectures
- Round table discussions

**Submitted Program**
- Oral & Poster presentations

**Thursday, December 15th 2016**

11:00-12:00 Welcome

**Session 1: New developments in cancer biomarkers**

12:00-12:30 Tumor-related neutrophils in cancer immunology and immunotherapy
  - Fridlender Z.G.
12:30-13:00 Immunomonitoring as a tool to identify biomarkers predicting the outcome of immunotherapy-treated patients
  - Gouttefangeas C.
13:00-13:30 Molecular determinants of immune responsiveness
  - Bedognetti D.
13:30-14:00 microRNAs
  - Scorilas A.
14:00-15:30 Light Lunch Break

**Session 2: Immune suppression in cancer**

15:30-16:00 Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer and progression
  - Pawelec G.
16:00-16:30 Myeloid-derived suppressor cells and their contribution to tumor immune escape
  - Bronte V.
16:30-17:00 Immunosuppression induced by chronic inflammation in melanoma
  - Umansky V.
17:00-17:30 Coffee break

**Session 3: Immune-oriented cancer therapies**

17:30-18:00 Autophagy pathway in tumor invasion
  - Verginis P.
18:00-18:30 Immuno-combination therapies for cancer
  - Adema G.
18:30-19:00 Anti-cancer vaccines: promises and obstacles
  - Kosmatopoulos K.
19:00-19:45 Clinical implication of tumor-derived exosomes in immunology of cancer
  - Whiteside T.L.
19:45 Welcome reception
Friday, December 16th 2016

SESSION 4: Immune stimulation in cancer

09:00-09:30 Natural Killer Cells and Cancer Immunotherapy  
Djeu J.

09:30-10:00 Molecularly targeted therapies  
Seliger B.

10:00-10:30 The role of chemokines in the regulation of cancer disease  
Karin N.

Plenary lecture

10:30-11:15 Immunotherapy Using CAR- and TCR-modified T Cells  
Eshhar Z.

11:15-11:30 Coffee break

11:30-12:15 Crosstalk between microbiota, pathogens and immune system: implication in cancer development and cancer immunotherapy  
O’Toole P.W.

Plenary lecture

12:15-13:00 Immune contexture and immunotherapy  
Fridman W.H.

13:00-14:30 Lunch break

14:30-16:30 Oral presentations
Moderators: R. Tsitsiloni, V. Georgoulias

16:30-17:00 Coffee break

SESSION 5: Immunotherapy (I) (non-small cell lung cancer)

17:00-17:20 Targeting immune checkpoints in NSCLC  
Kotsakis A.

17:20-17:40 Combination of radiation and immunotherapy  
Kouloulias V.

17:40-18:00 Combination of targeted therapies with immunotherapy  
Karachaliou N.

18:00-18:30 Coffee break

18:30-19:00 Combination of chemotherapy and immunotherapeutic approaches in NSCLC  
Karassaridi M.

19:00-19:30 State of the art in the treatment of NSCLC  
Berardi R.

Plenary lecture

19:30-20:15 The role of biomarkers in immunotherapy  
Peeters O.

Saturday, December 17th 2016

SESSION 6: Immunotherapy (II)

09:30-09:50 Advances in prostate cancer immunotherapy  
Baxevanis C.N.

09:50-10:10 Updated data for the immunotherapy of bladder cancer  
Tsiatas M.

10:10-10:30 Immunotherapy in renal carcinoma  
Krempel N.

10:30-10:50 Immunotherapy in breast cancer  
Szasz A.M.

10:50-11:10 Immune checkpoint inhibitor therapy for lymphomas  
Emmanouilides C.

11:10-11:30 Immunotherapy in squamous cell carcinoma of the head and neck  
Argiris A.

11:30-12:00 Coffee break

Plenary lecture

12:00-12:45 Immunotherapy in GI malignancies: Updated data  
Geva R.

12:45-13:30 Circulating tumor cells and epithelial to mesenchymal transition (EMT)  
Heymann D.

Plenary lecture

13:30-14:15 Advances in cancer immunology and immunotherapy  
Rivoltini L.

14:15-15:30 Lunch break

SESSION 7: Immunotherapy in melanoma

SESSION 7: Immunotherapy in melanoma

15:30-16:00 Targeting immune checkpoints in patients with advanced melanoma  
Metaxas I.

16:00-16:20 Treatment algorithm of Melanoma in the sunrise of 2017  
Bafaloukos D.

Coffee break

SESSION 8: Novel immunotherapeutic approaches

16:40-17:10 Targeting CD73 in the tumor microenvironment  
Whiteside T.L.

17:10-17:40 STING pathway: a novel target of immunotherapy  
Lavelle E.D.

17:40-18:10 Advancing Cancer Immunotherapy beyond Checkpoint Inhibitors  
Comis S.

18:10-18.40 Oncolytic virus in immuno-oncology: Current and future perspectives  
Nikolaou C.

Plenary lecture

18:40-19:15 Immunogenic cell death and novel approaches in cancer treatment  
Djeu J.

19:15-19:30 Closing remarks  
Djeu J., Whiteside T., Georgoulias V.

19:30-19:45 Award ceremony  
Djeu J., Whiteside T., Georgoulias V.
General Information

Organized by
Hellenic Society of Immuno-Oncology (HeSIO)
Lomvardou 55, Gkyzi
T.K. 11474, Athens, Greece
www.hellenic-immunooncology.gr

Dates
December 15th -17th 2016

Website:
http://hellenic-immunooncology.gr/2soio/

Symposium Venue
Royal Olympic Hotel, Athens
28-34, Athanasiou Diakou Str., 117 43, Athens, GREECE
Tel.: +30 210 92.88.400
Fax: +30 210 92.33.317
E-mail: info@royalolympic.com

Price per Delegate

<table>
<thead>
<tr>
<th>Category</th>
<th>Registration Fee</th>
<th>Webcasting Registration Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undergraduate students and postgraduate students</td>
<td>50€</td>
<td>25€</td>
</tr>
<tr>
<td>PhD students</td>
<td>100€</td>
<td>50€</td>
</tr>
<tr>
<td>Post-docs and MD</td>
<td>200€</td>
<td>150€</td>
</tr>
</tbody>
</table>

Certificate of Attendance
Based on the latest circular of the National Drug Organization the Event is required to use an attendance tracking system. All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance. By the end of the event a certificate will be given to those who have attended at least 60% of the total hours of the scientific Program.

Official Language
English is the official language of the Symposium.

Symposium Secretariat

Scientific Cultural Events and Publications
T +30 210 7240039 F +30 210 7240139 E info@scep.gr www.scep.gr